Abstract
Since the approval of rituximab (Rituxan®) for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) in 1997, nine additional monoclonal antibodies (mAbs) have been approved by the FDA for cancer therapy. Currently, more than 1,300 clinical studies registered at ClinicalTrials.gov investigate mAb therapy of cancer, including more than 150 phase III clinical trials. In concert with their clinical acceptance, mAbs in oncology have become commercially attractive. Four out of the ten approved mAbs have reached blockbuster status with annual sales exceeding $1 billion. The top three selling cancer drugs are all mAbs. These numbers indicate the potential of mAbs to play a leading role in cancer therapy for decades to come. Although mAbs provide a proven drug platform beyond the proof-of-concept stage, future success will depend on broadening and potentiating mAb therapy through antigen discovery, antibody engineering, use of mAbs in combination with chemotherapy and radiotherapy, and personalized medicine.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
http://www.landesbioscience.com/journals/mabs/about#background. Accessed June 23, 2010.
- 2.
Maggon K (2009) Global monoclonal antibodies market review 2008. http://knol.google.com. Accessed January 9, 2010.
- 3.
Maggon K (2009) Global cancer market review 2008. http://knol.google.com. Accessed January 9, 2010.
References
Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305:200–205
Dimitrov DS, Marks JD (2009) Therapeutic antibodies: current state and future trends – is a paradigm change coming soon? Methods Mol Biol 525:1–27, xiii
Reichert JM (2008) Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 9:423–430
Baker M (2005) Upping the ante on antibodies. Nat Biotechnol 23:1065–1072
Reichert JM, Valge-Archer VE (2007) Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6:349–356
Reichert JM, Rosensweig CJ, Faden LB et al (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23:1073–1078
Scott CT (2005) The problem with potency. Nat Biotechnol 23:1037–1039
Major EO (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61:35–47
Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 113:4834–4840
Suntharalingam G, Perry MR, Ward S et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018–1028
Waldmann TA (2006) Effective cancer therapy through immunomodulation. Annu Rev Med 57:65–81
Berger R, Rotem-Yehudar R, Slama G et al (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14:3044–3051
Fong L, Small EJ (2008) Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26:5275–5283
Hwang WY, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3–10
Tabrizi MA, Tseng CM, Roskos LK (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11:81–88
Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 359:613–626
Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147–159
Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273–286
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62
Ran S, Downes A, Thorpe PE (2002) Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62:6132–6140
Weiner LM (2007) Building better magic bullets – improving unconjugated monoclonal antibody therapy for cancer. Nat Rev Cancer 7:701–706
Attia P, Phan GQ, Maker AV et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043–6053
Hodi FS, Butler M, Oble DA et al (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105:3005–3010
Lipton A, Steger GG, Figueroa J et al (2007) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25:4431–4437
Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3:488–499
Weiner GJ (2007) Monoclonal antibody mechanisms of action in cancer. Immunol Res 39:271–278
Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671–680
Grunwald V, Hidalgo M (2003) Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95:851–867
Stel AJ, Ten Cate B, Jacobs S et al (2007) Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to Fas-induced apoptosis. J Immunol 178:2287–2295
Pedersen IM, Buhl AM, Klausen P et al (2002) The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99:1314–1319
Wilson TR, Johnston PG, Longley DB (2009) Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 9:307–319
Rubinfeld B, Upadhyay A, Clark SL et al (2006) Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat Biotechnol 24:205–209
Lane D (2006) Designer combination therapy for cancer. Nat Biotechnol 24:163–164
Salfeld JG (2007) Isotype selection in antibody engineering. Nat Biotechnol 25:1369–1372
Cragg MS, Glennie MJ (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103:2738–2743
Racila E, Link BK, Weng WK et al (2008) A polymorphism in the complement component C1qa correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 14:6697–6703
Clynes RA, Towers TL, Presta LG et al (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443–446
Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940–3947
Musolino A, Naldi N, Bortesi B et al (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789–1796
Satoh M, Iida S, Shitara K (2006) Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 6:1161–1173
Desjarlais JR, Lazar GA, Zhukovsky EA et al (2007) Optimizing engagement of the immune system by anti-tumor antibodies: an engineer’s perspective. Drug Discov Today 12:898–910
Hilchey SP, Hyrien O, Mosmann TR et al (2009) Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. Blood 113:3809–3812
Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373:1033–1040
Pastan I, Hassan R, Fitzgerald DJ et al (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559–565
Kreitman RJ, Squires DR, Stetler-Stevenson M et al (2005) Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23:6719–6729
Kreitman RJ, Stetler-Stevenson M, Margulies I et al (2009) Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 27:2983–2990
Scott AM, Welt S (1997) Antibody-based immunological therapies. Curr Opin Immunol 9:717–722
Kaspar M, Zardi L, Neri D (2006) Fibronectin as target for tumor therapy. Int J Cancer 118:1331–1339
Davis TA, Maloney DG, Czerwinski DK et al (1998) Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin’s lymphoma without eradicating the malignant clone. Blood 92:1184–1190
Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343–357
Demarest SJ, Glaser SM (2008) Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 11:675–687
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497
Morrison SL, Johnson MJ, Herzenberg LA et al (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 81:6851–6855
Riechmann L, Clark M, Waldmann H et al (1988) Reshaping human antibodies for therapy. Nature 332:323–327
Ritter G, Cohen LS, Williams C, Jr. et al (2001) Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 61:6851–6859
Aarden L, Ruuls SR, Wolbink G (2008) Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 20:431–435
DeNardo GL, Bradt BM, Mirick GR et al (2003) Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol Immunother 52:309–316
Chung CH, Mirakhur B, Chan E et al (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358:1109–1117
Clark M (2000) Antibody humanization: a case of the ‘emperor’s new clothes’? Immunol Today 21:397–402
Jakobovits A, Amado RG, Yang X et al (2007) From xenomouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25:1134–1143
Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23:1117–1125
Bain B, Brazil M (2003) Adalimumab. Nat Rev Drug Discov 2:693-694
Rader C (2001) Antibody libraries in drug and target discovery. Drug Discov Today 6:36–43
Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23:1105–1116
Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–725
Rader C, Sinha SC, Popkov M et al (2003) Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. Proc Natl Acad Sci U S A 100:5396–5400
Hofer T, Thomas JD, Burke TR Jr. et al (2008) An engineered selenocysteine defines a unique class of antibody derivatives. Proc Natl Acad Sci U S A 105:12451–12456
Woodnutt G, Violand B, North M (2008) Advances in protein therapeutics. Curr Opin Drug Discov Dev 11:754–761
Hudson PJ, Souriau C (2003) Engineered antibodies. Nat Med 9:129–134
Nelson AL, Reichert JM (2009) Development trends for therapeutic antibody fragments. Nat Biotechnol 27:331–337
Holt LJ, Herring C, Jespers LS et al (2003) Domain antibodies: proteins for therapy. Trends Biotechnol 21:484–490
Vincke C, Loris R, Saerens D et al (2009) General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 284:3273–3284
Chames P, Baty D (2009) Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Dev 12:276–283
Baeuerle PA, Kufer P, Bargou R (2009) BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 11:22–30
Bargou R, Leo E, Zugmaier G et al (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:974–977
Wu C, Ying H, Grinnell C et al (2007) Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 25:1290–1297
Bostrom J, Yu SF, Kan D et al (2009) Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323:1610–1614
Shen J, Zhu Z (2008) Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr Opin Mol Ther 10:273–284
Niculescu-Duvaz I (2004) Technology evaluation: EMD-273063, EMD lexigen. Curr Opin Mol Ther 6:559–566
Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676
O’Mahony D, Bishop MR (2006) Monoclonal antibody therapy. Front Biosci 11:1620–1635
Rader C, Bishop MR (2007) Monoclonal antibodies in cancer therapy. In: Kaufman HL, Wolchok JD (eds) General principles of tumor immunotherapy: basic and clinical applications of tumor immunology. Springer, Dordrecht
Grillo-Lopez AJ (2003) Rituximab (rituxan/MabThera): the first decade (1993–2003). Expert Rev Anticancer Ther 3:767–779
Cvetkovic RS, Perry CM (2006) Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 66:791–820
Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242
Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23:4117–4126
Habermann TM, Weller EA, Morrison VA et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121–3127
Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with chop alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725–3732
Teeling JL, Mackus WJ, Wiegman LJ et al (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177:362–371
Castillo J, Milani C, Mendez-Allwood D (2009) Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs 18:491–500
Witzig TE, Gordon LI, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463
Witzig TE, Molina A, Gordon LI et al (2007) Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 109:1804–1810
Czuczman MS, Emmanouilides C, Darif M et al (2007) Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 25:4285–4292
Morschhauser F, Radford J, Van Hoof A et al (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156–5164
Peipp M, Dechant M, Valerius T (2008) Effector mechanisms of therapeutic antibodies against ERBB receptors. Curr Opin Immunol 20:436–443
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
Crone SA, Zhao YY, Fan L et al (2002) Erbb2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459–465
Chien KR (2006) Herceptin and the hear – a molecular modifier of cardiac failure. N Engl J Med 354:789–790
Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820
Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345
Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048
Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765
Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634
Allegra CJ, Jessup JM, Somerfield MR et al (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096
Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712
Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578
Hopper-Borge EA, Nasto RE, Ratushny V et al (2009) Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 13:339–362
Bedard PL, de Azambuja E, Cardoso F (2009) Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets 9:148–162
Dancey JE, Chen HX (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 5:649–659
Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28–39
Lu D, Zhang H, Koo H et al (2005) A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280:19665–19672
Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342
Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550
Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563–572
Hecht JR, Mitchell E, Chidiac T et al (2009) A randomized phase IIIb trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672–680
Mayer RJ (2009) Targeted therapy for advanced colorectal cancer – more is not always better. N Engl J Med 360:623–625
Acknowledgements
I thank members of my laboratory for comments on the manuscript, in particular Lauren R. Skeffington and Drs. Sivasubramanian Baskar, Thomas Hofer, Brian C. Shaffer, and Jiahui Yang. This work was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Rader, C. (2011). Monoclonal Antibody Therapy for Cancer. In: Medin, J., Fowler, D. (eds) Experimental and Applied Immunotherapy. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-980-2_3
Download citation
DOI: https://doi.org/10.1007/978-1-60761-980-2_3
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-979-6
Online ISBN: 978-1-60761-980-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)